Article info
PDFClinical aspects
Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
- Correspondence to:
Dr M C Hochberg, 10 S Pine St, MSTF 8-34, Baltimore, MD 21201 USA;
mhochber{at}umaryland.edu
Citation
Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
Online issue publication
April 13, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2003 by Annals of the Rheumatic Diseases